Future studies using a chemically-induced orthotopic model of colon cancer using anti-CCL2 in combination with 5-FU while using DRS to monitor treatment response can provide clinicians more clinically relevant evidence of using cytokine-targeted therapy in CRC. This evidence concerns the gene CCL2 and malignant colon neoplasm.